Cargando…
Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer
Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019274/ https://www.ncbi.nlm.nih.gov/pubmed/35582024 http://dx.doi.org/10.20517/cdr.2020.81 |
_version_ | 1784689224052637696 |
---|---|
author | Benko, Aleksandra Medina-Cruz, David Vernet-Crua, Ada O’Connell, Catherine P. Świętek, Małgorzata Barabadi, Hamed Saravanan, Muthupandian Webster, Thomas J. |
author_facet | Benko, Aleksandra Medina-Cruz, David Vernet-Crua, Ada O’Connell, Catherine P. Świętek, Małgorzata Barabadi, Hamed Saravanan, Muthupandian Webster, Thomas J. |
author_sort | Benko, Aleksandra |
collection | PubMed |
description | Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors. |
format | Online Article Text |
id | pubmed-9019274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90192742022-05-16 Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer Benko, Aleksandra Medina-Cruz, David Vernet-Crua, Ada O’Connell, Catherine P. Świętek, Małgorzata Barabadi, Hamed Saravanan, Muthupandian Webster, Thomas J. Cancer Drug Resist Review Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors. OAE Publishing Inc. 2021-06-19 /pmc/articles/PMC9019274/ /pubmed/35582024 http://dx.doi.org/10.20517/cdr.2020.81 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Benko, Aleksandra Medina-Cruz, David Vernet-Crua, Ada O’Connell, Catherine P. Świętek, Małgorzata Barabadi, Hamed Saravanan, Muthupandian Webster, Thomas J. Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title | Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title_full | Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title_fullStr | Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title_full_unstemmed | Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title_short | Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
title_sort | nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019274/ https://www.ncbi.nlm.nih.gov/pubmed/35582024 http://dx.doi.org/10.20517/cdr.2020.81 |
work_keys_str_mv | AT benkoaleksandra nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT medinacruzdavid nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT vernetcruaada nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT oconnellcatherinep nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT swietekmałgorzata nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT barabadihamed nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT saravananmuthupandian nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer AT websterthomasj nanocarrierdrugresistanttumorinteractionsnovelapproachestofightdrugresistanceincancer |